chufangao/CTO huggingface dataset:
Clinical trial NCT02842580: De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer
Official title: Randomized Phase II Study Assessing the Efficacy and Safety of 2 Therapeutic Strategies Combining Bevacizumab With Chemotherapy: De-escalation Versus Escalation in Patients With Non-pretreated Unresectable Metastatic Colorectal Cancer
Acronym: HIGH-LIGHT
Sponsor: Federation Francophone de Cancerologie Digestive (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Inclusion rythm too slow.
Enrollment: 21.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-09-30
Primary completion date: 2020-10-31
Completion date: 2020-10-31
Baseline population: Baseline population is the ITT population meaning all the patients randomized into the study
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02525939: Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
Official title: A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial
Acronym: dal-GenE
Sponsor: DalCor Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 6147.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-04-30
Primary completion date: 2021-10-31
Completion date: 2021-10-31
Limitations and caveats: The main limitation of this study is the occurrence of the COVID-19 pandemic during study conduct.
Plan to share individual participant data: NO
Clinical trial NCT03322540: Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)
Official title: A Phase 2, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Versus Pembrolizumab Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 154.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-15
Primary completion date: 2019-01-10
Completion date: 2020-11-09
Baseline population: Intent-to-treat (ITT) population consisted of all randomized participants.
Plan to share individual participant data: NO
Clinical trial NCT01774487: Pentoxifylline Therapy in Biliary Atresia
Official title: A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia
Sponsor: Baylor College of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Target enrollment was not reached because the medication, pentoxifylline, has a taste that is not well tolerated by infants. The study team decided to end the study before meeting the enrollment goal because of the medication taste.
Enrollment: 17.0 (ACTUAL)
Number of arms: 1.0
Start date: 2013-02-04
Primary completion date: 2018-02-07
Completion date: 2023-02-20
Limitations and caveats: Because of early termination, this study did not reach the target number of participants needed to achieve target power and statistically reliable results.
Plan to share individual participant data: NO
IPD sharing description: The data for subjects will be shared in aggregate.
Clinical trial NCT02789254: FLYSYN in MRD Positive AML
Official title: First in Man Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Fc-optimized FLT3 Antibody FLYSYN for the Treatment of Acute Myeloid Leukemia Patients With Minimal Residual Disease
Acronym: FLYSYN-101
Sponsor: Synimmune GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 31.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-02-07
Primary completion date: 2021-09-27
Completion date: 2021-09-27
Plan to share individual participant data: UNDECIDED
IPD sharing description: publication
Clinical trial NCT04740827: Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
Official title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prophylaxis of Migraine in Participants With Episodic Migraine Who Have Previously Failed 2 to 4 Classes of Oral Prophylactic Treatments (ELEVATE)
Acronym: ELEVATE
Sponsor: Allergan (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 315.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-05
Primary completion date: 2022-08-04
Completion date: 2022-08-04
Baseline population: Intent-to-Treat (ITT) Population included all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Clinical trial NCT03491462: Arimoclomol in Amyotropic Lateral Sclerosis
Official title: A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis
Sponsor: ZevraDenmark (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 245.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-31
Primary completion date: 2020-12-18
Completion date: 2020-12-18
Baseline population: All participants in the modified intention-to-treat (mITT) population
Clinical trial NCT02256124: Effect of Lamotrigine on Cognition in NF1
Official title: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial (NF1-EXCEL)
Acronym: NF1-EXCEL
Sponsor: Erasmus Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Due to our experience, the small number of new inclusions, and the uncertainty regarding the COVID-19 outbreak, we have decided to discontinue the study.
Enrollment: 41.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-10-31
Primary completion date: 2020-04-30
Completion date: 2020-04-30
Clinical trial NCT02737930: Fluoxetine for Visual Recovery After Ischemic Stroke
Official title: Fluoxetine for Visual Recovery After Ischemic Stroke
Acronym: FLUORESCE
Sponsor: University of Rochester (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow recruitment and lack of funding to expand to other sites.
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-05-31
Primary completion date: 2020-08-31
Completion date: 2020-08-31
Clinical trial NCT03123289: Novel Gallium 68 Citrate in Orthopedic Infections
Official title: Novel Gallium 68 Citrate in Orthopedic Infections
Sponsor: Rutgers, The State University of New Jersey (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: PI left the institute and the funding expired.
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-03-06
Primary completion date: 2020-10-14
Completion date: 2020-10-14
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05166031: Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio Vaccine
Official title: A Phase III Study to Evaluate the Immunogenicity and Safety of Concomitant Administration of Two Doses of a Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio Vaccine in Healthy Infants
Sponsor: Fidec Corporation (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Sponsor decided not to conduct it
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-12-31
Primary completion date: 2021-04-30
Completion date: 2021-10-18
Clinical trial NCT01869361: Indomethacin for Tocolysis of Preterm Labor
Official title: Randomized, Placebo Controlled Trial of Indomethacin for Tocolysis
Sponsor: MetroHealth Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Due to much lower than expected numbers of eligible patients and lack of PI time, the study was not started.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-01
Primary completion date: 2021-11-23
Completion date: 2021-11-23
Clinical trial NCT03897062: Suvorexant in the Management Comorbid Sleep Disorder and Alcohol Dependence
Official title: A Placebo-controlled, Double -Blind Randomised Trial of Suvorexant in the Management Comorbid Sleep Disorder and Alcohol Dependence
Sponsor: The Florey Institute of Neuroscience and Mental Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Recruitment problems during covid lockdowns resulted in Merck ceasing supply of suvorexant/placebo
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-26
Primary completion date: 2022-07-31
Completion date: 2022-07-31
Plan to share individual participant data: NO
Clinical trial NCT03461406: A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants
Official title: A Prospective, Randomized, Active-Controlled, Single-blind, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Haemostasis During Surgery in Paediatric Subjects
Sponsor: Grifols Therapeutics LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 186.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-18
Primary completion date: 2022-04-15
Completion date: 2022-05-20
Baseline population: Intent-to-Treat (ITT) population included all participants who were randomized, regardless of meeting intra-operative enrollment criteria and regardless of whether the IP was administered to the participant.
Plan to share individual participant data: NO
Clinical trial NCT02884908: Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD
Official title: Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD
Sponsor: University of Maryland, Baltimore (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 57.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-07-07
Primary completion date: 2022-01-19
Completion date: 2022-01-19
Limitations and caveats: Sample size calculated for effect size=0.31, attrition=25%, correlation among repeated measures=0.55. With power=0.80 \& alpha-level=.05/2=.025, N=198 randomized. Due to interruptions/pandemic, N=57 randomized; final analysis N=44 (26 pregabalin/18 placebo). Re-calculated power based on modified primary analysis, achieved sample size, observed attrition rates (40%), \& average correlation among repeated measures. Aim1 effect size=0.67, 2-sided alpha=0.05, power=0.80. Aim2 effect sizes=0.68 \& 0.63.
Plan to share individual participant data: YES
IPD sharing description: Following the NIH policy, and the Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources, the investigators will provide all of our research resources available for research purposes to qualified individuals within the scientific community after publication of our results.~Sharing of all of the research resources generated by this funded project will be in accordance with the federal rules or regulations imposed upon by the University of Maryland, Baltimore. The investigators will make the results available in accordance with the NIH Data Sharing policy. The investigators will analyze data and submit for peer reviewed publications in scientific journals. The investigators will also present the data in scientific meetings, symposia, or other scientific communications consistent with academic standards.
Clinical trial NCT04575818: A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059
Official title: A First-in-human, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of GLPG4059 in Adult, Healthy, Male Subjects
Sponsor: Galapagos NV (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Development of compound has been stopped
Enrollment: 32.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-09-16
Primary completion date: 2021-04-08
Completion date: 2021-04-08
Plan to share individual participant data: NO
Clinical trial NCT03055312: Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer
Official title: A Randomized, Multicenter,Phase III Study of Bicalutamide Versus Chemotherapy in First Line Treatment of AR Positive Metastatic Triple Negative Breast Cancer
Acronym: SYSUCC-007
Sponsor: Sun Yat-sen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Enrollment: 36.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-12-20
Primary completion date: 2020-11-15
Completion date: 2020-11-15
Plan to share individual participant data: NO
Clinical trial NCT05158296: Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
Official title: A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
Sponsor: Laboratoires Thea (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 7.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-12-08
Primary completion date: 2022-10-12
Completion date: 2022-10-12
Limitations and caveats: Study prematurely terminated due to sponsor decision for reasons unrelated to safety.
Plan to share individual participant data: NO
Clinical trial NCT03236649: The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
Official title: Comparison of Efficacy and Safety of Icaritin Versus Sorafenib in First-line Treatment of PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects: a Multicenter, Randomized, Opened Phase III Clinical Trial
Sponsor: Beijing Shenogen Biomedical Co., Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Because the clinical development plan has been changed.
Enrollment: 89.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-20
Primary completion date: 2022-02-08
Completion date: 2022-02-08
Clinical trial NCT04155190: An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
Official title: A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 2 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Patients With Non-Gorlin High Frequency BCC
Sponsor: Sol-Gel Technologies, Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Terminated early due to low blinded event rate
Enrollment: 47.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-20
Primary completion date: 2021-04-23
Completion date: 2021-04-23
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02689141: Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
Official title: Prospective, Open-label, Multicentre Phase-II Trial to Evaluate Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by Ofatumumab and Ibrutinib Followed by Ibrutinib and Ofatumumab Maintenance in CLL Patients
Sponsor: German CLL Study Group (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 66.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-02-04
Primary completion date: 2017-07-13
Completion date: 2020-02-06
Plan to share individual participant data: NO
Clinical trial NCT03151772: Bioavailability of Disulfiram and Metformin in Glioblastomas
Official title: Drug Level and Investigation of Novel Substances Indicated Downstream Effect in Glioblastoma
Acronym: INSIDE
Sponsor: Sahlgrenska University Hospital, Sweden (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Problems with including patients
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-29
Primary completion date: 2020-09-24
Completion date: 2020-09-24
Plan to share individual participant data: NO
Clinical trial NCT05003102: Dexmedetomidine Cycling and Sleep in the Pediatric ICU
Official title: Dexmedetomidine Cycling and Sleep in the Pediatric ICU
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: No enrollment, IRB closed
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-02-20
Primary completion date: 2023-06-30
Completion date: 2023-06-30
Plan to share individual participant data: NO
IPD sharing description: There is no plan to make IPD available to other researchers
Clinical trial NCT04492358: Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center
Official title: Phase 2/3, Randomized, Open Study to Compare the Efficacy and Safety of Colchicine and Glucocorticoids Compared With the Standard of Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center
Sponsor: Fundacion Clinic per a la Recerca Biomédica (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: No candidates for the recruitment
Enrollment: 54.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-22
Primary completion date: 2021-05-31
Completion date: 2021-05-31
Clinical trial NCT04342689: The Role of Resistant Starch in COVID-19 Infection
Official title: The Role of Resistant Starch in COVID-19 Infection
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Study was terminated due to low enrollment.
Enrollment: 226.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-03
Primary completion date: 2021-04-15
Completion date: 2021-04-15
Plan to share individual participant data: YES
IPD sharing description: Deidentified data underlying results for publication are planned to be made available after publication.
IPD time frame: After publication, indefinitely
Clinical trial NCT04790487: Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis
Official title: A Randomized Placebo Control Trial to Evaluate the Efficacy of Chlorpheniramine Maleate Nasal Spray vs. Placebo for Acute or Chronic Rhinitis
Sponsor: Larkin Community Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Study Period Ended/Not Completed
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-30
Primary completion date: 2020-12-30
Completion date: 2021-12-30
Plan to share individual participant data: NO
Clinical trial NCT05516849: Placebo Versus Oxandrolone Supplementation in Trauma
Official title: Placebo Versus Oxandrolone Supplementation in Trauma: A Randomized Multi-Center Double Blind Clinical Trial in High-Energy Lower Extremity Trauma (POST-Injury Trial)
Sponsor: Sunnybrook Health Sciences Centre (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: FDA requested manufacturers of Oxandrolone Tablets, to voluntarily remove previously approved drug applications for Oxandrolone from the U.S. market \& the funding decided to prematurely terminate the funding.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-19
Primary completion date: 2023-08-03
Completion date: 2023-08-03
Plan to share individual participant data: NO
Clinical trial NCT04610827: Oral Iron Frequency for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder
Official title: Optimum Frequency and Timing of Oral Iron Administration for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Change in personnel and lack of resources to continue.
Enrollment: 6.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-11-16
Primary completion date: 2021-06-29
Completion date: 2021-06-29
Limitations and caveats: Study terminated due to change in personnel and lack of resources to continue.
Plan to share individual participant data: NO
Clinical trial NCT04580277: Tofacitinib For Treatment Of Chronic Pouchitis
Official title: A Single Center Open-Label Prospective Study Of Oral Tofacitinib In Patients With Chronic Pouchitis
Sponsor: Cedars-Sinai Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: low recruitment
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-01-25
Primary completion date: 2022-12-01
Completion date: 2023-05-15
Limitations and caveats: Limitations of this study included a single center design, small sample size, and absence of a control arm. This study also lacked long-term follow-up data to assess durability of response to tofacitinib and its long-term safety in chronic pouchitis. This study also only included patients with chronic pouchitis and its findings may not be applicable to other chronic inflammatory pouch disorders. Study recruitment was terminated prematurely due to COVID-19 pandemic-related recruitment challenges.
Clinical trial NCT02720601: Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers
Official title: A Phase II Trial of Combination Irinotecan and Capecitabine as Second-Line Treatment for Patients With Locally Advanced/Metastatic Biliary Tract Cancers Who Progressed or Intolerant to Front-Line Gemcitabine and Platinum Combination
Sponsor: New Mexico Cancer Care Alliance (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study was never submitted to the IRB \& never opened. PI is leaving institution.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-11-30
Primary completion date: 2018-03-31
Completion date: 2020-03-31
Clinical trial NCT04411602: Intermediate IND Severe Illness COVID-19 CP
Official title: Intermediate IND Severe Illness COVID-19 CP
Sponsor: Ascension South East Michigan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: No participants due to waning pandemic.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-04-07
Primary completion date: 2021-04-07
Completion date: 2021-04-07